Implications of personalized medicine—perspective from a cancer center
- 2 March 2011
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 8 (3), 177-183
- https://doi.org/10.1038/nrclinonc.2010.222
Abstract
Three advances are dramatically changing the landscape of oncology. First, hundreds of drugs are available that inhibit targets involved in oncogenesis. Second, efforts to reclassify malignant diseases are expanding the number of orphan molecular diseases. Third, the implementation of high-throughput technologies will allow risk of relapse prediction and drug sensitivity. Patients predicted to relapse will be referred to comprehensive cancer centers where new drugs will be tested. It is anticipated that a high number of small, biology-driven clinical trials will report high sensitivity to targeted agents in rare biologically defined diseases. Drug registration and biomarker analysis needs to be revisited to avoid large phase III trials with control arms. The use of high-throughput technologies will lead to the development of virtual cells. These considerations highlight the need for developing a consortium of comprehensive cancer centers to run clinical trials in rare, molecularly-defined populations, and implement high-throughput technologies for daily practice.Keywords
This publication has 41 references indexed in Scilit:
- Whole-genome cancer analysis as an approach to deeper understanding of tumour biologyBritish Journal of Cancer, 2009
- Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell lineProceedings of the National Academy of Sciences of the United States of America, 2009
- Transcriptome sequencing to detect gene fusions in cancerNature, 2009
- DNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeNature, 2008
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerThe Lancet Oncology, 2008
- Patterns of somatic mutation in human cancer genomesNature, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- A census of human cancer genesNature Reviews Cancer, 2004